Olle Ljungqvist MD PhD
Past Chairman ERAS®Society
Professor of Surgery
Örebro University Hospital & Karolinska Institutet
Sweden
Improving Perioperative Care Worldwide
ERAS worldwide August 2022
Disclosure for Olle Ljungqvist
In compliance with COI policy, ESCRS requires the following disclosures to the session audience:
Presentation does not include discussion of off-label use of a drugs or medical devices
8th ERAS World Congress
2
www.erassociety.org
Shareholder | Encare AB (SE) |
Grant / Research Support | No relevant conflicts of interest to declare. |
Consultant/advisor | Nutricia (NL), Pharmacomsos (DK |
Employee | No relevant conflicts of interest to declare. |
Paid Instructor | No relevant conflicts of interest to declare. |
Speaker Bureau | Medtronic, Nutricia, BBraun, Fresenius |
Other | Previous patent for preoperative carbohydrate drink |
Share some thoughts
What ERAS®Society has done
Complications Hospital stay
Guideline compliance
50%
100%
ERAS and Survival?
Recent Review
Variability in ERAS protocol items
Pang et al, W J Surg Oncol 2021: 19: 191
ERAS and long term survival
What is available?
ERAS vs Non ERAS Prospective cohorts 8 studies ≈ 1000 pats, 6 surgeries
ERAS vs Non ERAS RCT 2 studies ≈350 pats 4 different operations
ERAS vs Non ERAS 7 Retrospective cohorts ≈ 4450 pats, 6 surgeries
1 – 10 year follow up
Summary: 12 studies NS
5 studies improved survival
Pang et al, W J Surg Oncol 2021: 19: 191
Adherence to guidelines and survival
Summary: OS 3 studies improved survival
3 studies NS
CSS 1 study improved survival
DFS 1 study improved survival
1 study NS
Prospective cohort ≈750 pats, 2 surgeries
Retrospective cohort ≈ 1325 pats, 4 surgeries
Pang et al, W J Surg Oncol 2021: 19: 191
Return to Intended Oncologic Treatment (RIOT)
Delayed RIOT: Complications or poor performance
Risk factors: Hypertension
Mutiple preop chemo
Postop complications
MIS more and faster RIOT vs open surgery
Return to Intended Oncologic Treatment (RIOT)
Pang et al, W J Surg Oncol 2021: 19: 191
ERAS and long term survival after cancer surgery
ERAS survival effect mainly in advanced CR cancer
Factor ERAS Traditional
n = 70 n = 279
Complications 17% 31%
Length of stay 5d 10d
Colorectal cancer surgery
1 ERAS trained surgeon
4 ”traditional” surgeons
5 year follow up
Lohsiriwat V et al Updates Surgery 2021: 73: 2169-2179
Controlling stress metabolism with ERAS�Insulin resistance
Insulin sensitvity
Bowel prep
No nutrition
Dinner, normal sleep
Carbohydrate treatment
Overnight fasting
Thoracic Epidural
Preoperative sedation
Surgery
Immediate feeding & mobilisation
NPO iv low caloric fluids
Oral feeding & mobilisation
Slow return to feeding and mobilisation
Days - weeks
ERAS Care
Traditional care
Ljungqvist JPEN 2012
Insulin reistance
Catabolism
Anabolic
Can ERAS affect residual tumor cells?
Horowitz et al, Nat Rev Clin Onc 2015; 12:213-226
Long term outcomes cancer surgery
Where is surgical care today?�And why?
21st century surgery �World Health Organization
Complications 1 in 4
Death 1 in 20 – 200
Surgery cause 1 in 2 adverse events
Half preventable
https://www.who.int/teams/integrated-health-services/patient-safety/research/safe-surgery
Variation in complications - Sweden
Complications (%)
?
Nat’l 25%
38%
13%
Why different?
Standardized
Little standardised
Different worlds?
Control a machine, best practice established, weather
No standard of care, many unknowns, human variation
What we learned about�”Standard of care”
Standard of care?
PRE
INTRA
POST
What is failing?
Antibiotics
PONV
Thrombosis
NG tubes
Fluids
Fasting guidelines
Temperature control
?
DRinking EAting Mobilising
It is not
the care you believe is being delivered
It is
knowing you deliver the right care
ERAS startingpoint�Finding the knowledge for a standard of care
Data in surgery world wide
Meaningful data
Helps improves outcomes
Use data correctly
Fearon et al, Clin Nutr 2005
All care that Improve Recovery
Multi disciplinary Entire patient journey Multi professional
Anesthesia
Bariatric*
Breast reconstruction*
Cardiac°
Cesarean delivery
Colorectal and small bowel*
Cystectomy*
Cytoreductive Surgery
Esophagectomy
Gastrectomy
Gastrointestinal
Gynecology* Head & Neck*
�
ERAS® Society Guidelines
* Guideline is currently supported in the ERAS® Interactive Audit System
°Guideline is currently in progress to be supported in the new ERAS® Interactive Audit System
Hip replacement°
Liver*
Neonatal intestinal
Pancreaticoduodenectomy*
Thoracic°
Emergency laparotomy Part 1
2022
AAA open surgery
ERAS for LMIC
ERAS Liver Transplantation
Emergency Laparotomy part 2-3
Surgical care evidence for guidence
Experience
Science
A common probelm world wide
Staff are leaving
Factors that keep staff on the job
ERAS®Society Regional Networks
39
ERAS®USA
ERAS®Canada
ERAS®LaTAM
ERAS®Africa
ERAS®Asia
ERAS®Society
The Future of ERAS
Wish List
Challenges
Approach to the challenges ahead
Respect
Curiosity
Sharing
Trust